[
    [
        {
            "time": "2018-04-01",
            "original_text": "Roche Hemophilia Drug Gets Breakthrough Therapy Designation",
            "features": {
                "keywords": [
                    "Roche",
                    "Hemophilia",
                    "Drug",
                    "Breakthrough",
                    "Therapy",
                    "Designation"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Roche Hemophilia Drug Gets Breakthrough Therapy Designation",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-04-01",
            "original_text": "Gilead Sciences May Witness Significant Drop in Revenues in 2018",
            "features": {
                "keywords": [
                    "Gilead",
                    "Sciences",
                    "Drop",
                    "Revenues",
                    "2018"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Gilead Sciences May Witness Significant Drop in Revenues in 2018",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-04-01",
            "original_text": "What Analysts Recommend for Gilead Sciences in April 2018",
            "features": {
                "keywords": [
                    "Analysts",
                    "Recommend",
                    "Gilead",
                    "Sciences",
                    "April",
                    "2018"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "What Analysts Recommend for Gilead Sciences in April 2018",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-04-01",
            "original_text": "The Zacks Analyst Blog Highlights: AbbVie, Berkshire Hathaway, PepsiCo, BP and Twenty-First Century Fox",
            "features": {
                "keywords": [
                    "Zacks",
                    "Analyst",
                    "Blog",
                    "Highlights",
                    "AbbVie",
                    "Berkshire",
                    "Hathaway",
                    "PepsiCo",
                    "BP",
                    "Twenty-First",
                    "Century",
                    "Fox"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "consumer goods",
                    "energy",
                    "media"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "The Zacks Analyst Blog Highlights: AbbVie, Berkshire Hathaway, PepsiCo, BP and Twenty-First Century Fox",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 6,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-04-01",
            "original_text": "Analysts’ Recommendations for AbbVie in April 2018",
            "features": {
                "keywords": [
                    "Analysts",
                    "Recommendations",
                    "AbbVie",
                    "April",
                    "2018"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Analysts’ Recommendations for AbbVie in April 2018",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-04-01",
            "original_text": "AbbVie to Present at the Deutsche Bank's 43rd Annual Health Care Conference",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Present",
                    "Deutsche",
                    "Bank",
                    "Health",
                    "Care",
                    "Conference"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "AbbVie to Present at the Deutsche Bank's 43rd Annual Health Care Conference",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-04-01",
            "original_text": "AbbVie’s Duodopa, Creon, Synagis, Synthroid, and Sevoflurane",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Duodopa",
                    "Creon",
                    "Synagis",
                    "Synthroid",
                    "Sevoflurane"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie’s Duodopa, Creon, Synagis, Synthroid, and Sevoflurane",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 4,
                "Headline_Structure": 6,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-04-01",
            "original_text": "5 Drug Stocks Poised to Surpass on Earnings This Quarter",
            "features": {
                "keywords": [
                    "Drug",
                    "Stocks",
                    "Poised",
                    "Surpass",
                    "Earnings",
                    "Quarter"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "5 Drug Stocks Poised to Surpass on Earnings This Quarter",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        }
    ]
]